SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!
201314zlj君
Lv1
10 积分
2023-06-25 加入
最近求助
最近应助
互助留言
CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC)
4天前
求助中
D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results
3个月前
已完结
抗肿瘤药物相关间质性肺病诊治专家共识
3个月前
已关闭
EGFR、VEGF 和Ki67在食管癌中的表达及其临床意义
4个月前
已完结
Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC)
4个月前
已关闭
A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma
4个月前
已完结
First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations
5个月前
已关闭
Cancer incidence and mortality in China, 2016
6个月前
已完结
2016年中国恶性肿瘤流行情况分析
6个月前
已完结
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
6个月前
已完结
没有进行任何应助
2023 AACR正文求助 First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations
5个月前
请问补充资料为啥求助不到?
6个月前
未应助【积分已退回】
10个月前
未获取【积分已退回】
10个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论